{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:32:19Z","timestamp":1785450739773,"version":"3.56.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T00:00:00Z","timestamp":1512345600000},"content-version":"vor","delay-in-days":764,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["bjanaesthesia.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["British Journal of Anaesthesia"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1093\/bja\/aev326","type":"journal-article","created":{"date-parts":[[2015,10,16]],"date-time":"2015-10-16T16:49:28Z","timestamp":1445014168000},"page":"761-767","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["Epidermal growth factor receptor \u2013 inhibition (EGFR-I) in the treatment of neuropathic pain"],"prefix":"10.1016","volume":"115","author":[{"given":"C.","family":"Kersten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.G.","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Laird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mj\u00e5land","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/bja\/aev326_bib1","series-title":"Classification of Chronic Pain","article-title":"Part III, Pain Terms, A Current List with Definitions and Notes on Usage","author":"IASP","year":"2014"},{"key":"10.1093\/bja\/aev326_bib2","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.ejca.2008.03.022","article-title":"Management of cancer pain: basic principles and neuropathic cancer pain","volume":"44","author":"Laird","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1093\/bja\/aev326_bib3","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2165\/00019053-200927020-00002","article-title":"Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy","volume":"27","author":"O'Connor","year":"2009","journal-title":"PharmacoEconomics"},{"key":"10.1093\/bja\/aev326_bib4","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.pain.2007.08.013","article-title":"Prevalence of chronic pain with neuropathic characteristics in the general population","volume":"136","author":"Bouhassira","year":"2008","journal-title":"Pain"},{"key":"10.1093\/bja\/aev326_bib5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0885-3924(94)00073-T","article-title":"Mood states of oncology outpatients: does pain make a difference?","volume":"10","author":"Glover","year":"1995","journal-title":"Journal of Pain & Symptom Management"},{"key":"10.1093\/bja\/aev326_bib6","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1191\/0269216304pm923oa","article-title":"A prospective study to determine the association between physical symptoms and depression in patients with advanced cancer","volume":"18","author":"Lloyd-Williams","year":"2004","journal-title":"Palliat Med"},{"key":"10.1093\/bja\/aev326_bib7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pain.2005.08.013","article-title":"Algorithm for neuropathic pain treatment: an evidence based proposal","volume":"118","author":"Finnerup","year":"2005","journal-title":"Pain"},{"key":"10.1093\/bja\/aev326_bib8","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/bmj.332.7549.1081","article-title":"Difficult pain","volume":"332","author":"Colvin","year":"2006","journal-title":"Br Med J"},{"key":"10.1093\/bja\/aev326_bib9","first-page":"205","article-title":"Opioid-resistant pain: sense or nonsense?","volume":"6","author":"Fallon","year":"1993","journal-title":"The Pain Clinic"},{"key":"10.1093\/bja\/aev326_bib10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0885-3924(99)00099-8","article-title":"Investigation of an opioid response categorization in advanced cancer patients","volume":"18","author":"Mercadante","year":"1999","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1093\/bja\/aev326_bib11","first-page":"1","article-title":"Cetuximab alleviates neuropathic pain despite tumour progression","author":"Kersten","year":"2012","journal-title":"BMJ Case Reports"},{"key":"10.1093\/bja\/aev326_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.sjpain.2012.11.011","article-title":"Epithelial growth factor receptor (EGFR)-inhibition for relief of neuropathic pain\u2014A case series","volume":"4","author":"Kersten","year":"2013","journal-title":"Scandinavian Journal of Pain"},{"key":"10.1093\/bja\/aev326_bib13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0092-8674(02)00940-6","article-title":"Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha","volume":"110","author":"Garrett","year":"2002","journal-title":"Cell"},{"key":"10.1093\/bja\/aev326_bib14","author":"Limited AU"},{"key":"10.1093\/bja\/aev326_bib15","author":"Limited RP"},{"key":"10.1093\/bja\/aev326_bib16","author":"Ltd"},{"key":"10.1093\/bja\/aev326_bib17","author":"Serono"},{"key":"10.1093\/bja\/aev326_bib18","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1212\/01.wnl.0000282763.29778.59","article-title":"Neuropathic pain: redefinition and a grading system for clinical and research purposes","volume":"70","author":"Treede","year":"2008","journal-title":"Neurology"},{"key":"10.1093\/bja\/aev326_bib19","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1185\/030079906X132488","article-title":"painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain","volume":"22","author":"Freynhagen","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1093\/bja\/aev326_bib20","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singapore"},{"key":"10.1093\/bja\/aev326_bib21","series-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1093\/bja\/aev326_bib22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0304-3959(01)00349-9","article-title":"Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale","volume":"94","author":"Farrar","year":"2001","journal-title":"Pain"},{"key":"10.1093\/bja\/aev326_bib23","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jama.2012.385","article-title":"Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial","volume":"307","author":"Alberts","year":"2012","journal-title":"JAMA"},{"key":"10.1093\/bja\/aev326_bib24","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1200\/JCO.2013.51.1816","article-title":"Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study","volume":"31","author":"Goss","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/bja\/aev326_bib25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2478\/raon-2013-0014","article-title":"A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis","volume":"47","author":"Ocvirk","year":"2013","journal-title":"Radiology and Oncology"},{"key":"10.1093\/bja\/aev326_bib26","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1523\/JNEUROSCI.17-05-01642.1997","article-title":"Expression of neuregulins and their putative receptors, ErbB2 and ErbB3, is induced during Wallerian degeneration","volume":"17","author":"Carroll","year":"1997","journal-title":"J Neurosci"},{"key":"10.1093\/bja\/aev326_bib27","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1002\/jnr.21364","article-title":"Activation of epidermal growth factor receptors in astrocytes: from development to neural injury","volume":"85","author":"Liu","year":"2007","journal-title":"J Neurosci Res"},{"key":"10.1093\/bja\/aev326_bib28","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.neulet.2011.12.023","article-title":"Expression changes of the neuregulin 1 isoforms in neuropathic pain model rats","volume":"508","author":"Kanzaki","year":"2012","journal-title":"Neurosci Lett"},{"key":"10.1093\/bja\/aev326_bib29","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/glia.21124","article-title":"Following nerve injury neuregulin-1 drives microglial proliferation and neuropathic pain via the MEK\/ERK pathway","volume":"59","author":"Calvo","year":"2011","journal-title":"Glia"},{"key":"10.1093\/bja\/aev326_bib30","first-page":"1455","volume":"39","author":"Oliveras-Ferraros","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1093\/bja\/aev326_bib31","first-page":"71","article-title":"Mitogen-activated protein kinases as potential targets for pain killers","volume":"5","author":"Ji","year":"2004","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1093\/bja\/aev326_bib32","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/nn1992","article-title":"The neuropathic pain triad: neurons, immune cells and glia","volume":"10","author":"Scholz","year":"2007","journal-title":"Nat Neurosci"},{"issue":"Pt 21","key":"10.1093\/bja\/aev326_bib33","first-page":"4939","article-title":"Functional expression of the voltage-gated Na(+)-channel Nav1.7 is necessary for EGF-mediated invasion in human non-small cell lung cancer cells","volume":"126","author":"Campbell","year":"2013","journal-title":"J Cell Sci"},{"key":"10.1093\/bja\/aev326_bib34","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1523\/JNEUROSCI.18-02-00590.1998","article-title":"Growth factor receptor tyrosine kinases acutely regulate neuronal sodium channels through the src signaling pathway","volume":"18","author":"Hilborn","year":"1998","journal-title":"J Neurosci"},{"issue":"Suppl 7","key":"10.1093\/bja\/aev326_bib35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1528-1167.2012.03712.x","article-title":"Why are antiepileptic drugs used for nonepileptic conditions?","volume":"53","author":"Bialer","year":"2012","journal-title":"Epilepsia"},{"key":"10.1093\/bja\/aev326_bib36","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(11)60613-2","article-title":"Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial","volume":"377","author":"Maughan","year":"2011","journal-title":"Lancet"},{"key":"10.1093\/bja\/aev326_bib37","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1200\/JCO.2011.38.0915","article-title":"Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study","volume":"30","author":"Tveit","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/bja\/aev326_bib38","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/AJP.0b013e31819ddded","article-title":"Predictors of placebo response in pooled lamotrigine neuropathic pain clinical trials","volume":"25","author":"Irizarry","year":"2009","journal-title":"Clin J Pain"},{"issue":"3","key":"10.1093\/bja\/aev326_bib39","article-title":"Gabapentin for acute and chronic pain","author":"Wiffen","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/bja\/aev326_bib40","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jpainsymman.2011.05.003","article-title":"A spicamycin derivative (KRN5500) provides neuropathic pain relief in patients with advanced cancer: a placebo-controlled, proof-of-concept trial","volume":"43","author":"Weinstein","year":"2012","journal-title":"J Pain Symptom Manage"},{"key":"10.1093\/bja\/aev326_bib41","doi-asserted-by":"crossref","first-page":"7723","DOI":"10.1073\/pnas.96.14.7723","article-title":"Transcriptional and posttranslational plasticity and the generation of inflammatory pain","volume":"96","author":"Woolf","year":"1999","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["British Journal of Anaesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091217310784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007091217310784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/bja\/article-pdf\/115\/5\/761\/624924\/aev326.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T18:33:53Z","timestamp":1757788433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007091217310784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0007091217310784"],"URL":"https:\/\/doi.org\/10.1093\/bja\/aev326","relation":{},"ISSN":["0007-0912"],"issn-type":[{"value":"0007-0912","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidermal growth factor receptor \u2013 inhibition (EGFR-I) in the treatment of neuropathic pain","name":"articletitle","label":"Article Title"},{"value":"British Journal of Anaesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1093\/bja\/aev326","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Author(s). Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}